Lupus Clinical Trials in New York, New York
32 recruitingNew York, New York
Showing 1–20 of 32 trials
Recruiting
Phase 1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Systemic Lupus ErythematosusAntiphospholipid Syndrome
Hospital for Special Surgery, New York700 enrolled10 locationsNCT00198068
Recruiting
Phase 2Phase 3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Biogen450 enrolled314 locationsNCT05531565
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled93 locationsNCT07015983
Recruiting
Phase 1Phase 2
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus ErythematosusLupus Nephritis
Cabaletta Bio28 enrolled23 locationsNCT06121297
Recruiting
Phase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
AstraZeneca100 enrolled97 locationsNCT05835310
Recruiting
Phase 1
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Systemic SclerosisIdiopathic Inflammatory MyopathySystemic Lupus Erythematosus (With and Without Nephritis)
Allogene Therapeutics66 enrolled13 locationsNCT07085104
Recruiting
Phase 4
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Bristol-Myers Squibb35 enrolled4 locationsNCT06875960
Recruiting
Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
SLESLE (Systemic Lupus)
Cullinan Therapeutics Inc.24 enrolled15 locationsNCT06613360
Recruiting
Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 2
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Lupus Nephritis
Children's Hospital Medical Center, Cincinnati105 enrolled19 locationsNCT05538208
Recruiting
Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
AstraZeneca302 enrolled272 locationsNCT06015737
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Lupus NephritisPrimary Membranous Nephropathy
Nkarta, Inc.96 enrolled16 locationsNCT06557265
Recruiting
Phase 3
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Systemic Lupus Erythematosus
NYU Langone Health330 enrolled10 locationsNCT05799378
Recruiting
Phase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled52 locationsNCT06570798
Recruiting
Phase 1
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955
Recruiting
Early Phase 1
Safety and Efficacy of ONT01 in Lupus
Systemic Lupus ErythematosusSLELupus Nephritis (LN)+5 more
Hospital for Special Surgery, New York61 enrolled1 locationNCT07107659
Recruiting
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Kidney DiseasesDiabetic NephropathyKidney Failure, Chronic+2 more
The Rogosin Institute2,000 enrolled1 locationNCT01802034
Recruiting
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
Lupus Erythematosus, Systemic
Ampel BioSolutions, LLC200 enrolled11 locationsNCT05845593